Token is not live yet. Please beware of scams.
3.7 C
New York

Differentiation Between Healthy Cerebral Tissue and Tumor Tissue Using a Tissue Sensing Instrument

Date:

Node: 207101

Studies

Study First Submitted Date 2021-12-11
Study First Posted Date 2021-12-28
Last Update Posted Date 2023-03-09
Start Month Year April 30, 2019
Primary Completion Month Year December 31, 2022
Verification Month Year March 2023
Verification Date 2023-03-31
Last Update Posted Date 2023-03-09

Detailed Descriptions

Sequence: 20753009
Description Background: Diffuse reflectance spectroscopy is an optically based technique which measures the amount of diffusely reflected light after it has undergone multiple scattering and absorption events within the tissue. Each DRS spectrum therefore has a specific 'optical fingerprint' reflecting the composition and morphology of the tissue within the probing volume. The technology is easily built into very small instruments that can be fused with regularly used surgical equipment. DRS has previously been widely investigated for the purpose of margin assessment in other regions of the body. Aim & Hypothesis: The primary goal is to show the feasibility of applying optical tissue sensing using diffuse reflectance spectroscopy (DRS) to differentiate healthy cerebral tissue from tumorous tissue in ex vivo human tissue samples. This will be a basis for further development of surgical equipment able to identify the margin between healthy brain tissue and tumor tissue intraoperatively. Method: Using DRS we aim to determine spectroscopy thresholds that enables differentiation of cerebral tissue from different forms of tumor tissue. We aim to determine these thresholds by collecting DRS data on ex vivo brain and tumor samples. The tumor samples will be part of the normal extraction of tissue during tumor surgeries and the non tumorous tissue can be extracted in temporal/frontal lobe resections as well as epilepsy surgery, where non tumorous brain tissue is to be removed. The DRS measurements are performed in direct connection to the extraction of tissue during surgery, and the tissue is thereafter sent to the pathologist according to standard clinical procedures. No extra tissue will need to be resected for the purpose of this study. Based on the experiments we will propose a theoretical model for differentiating normal cerebral tissue from tumor tissue in humans for use during surgery.

Facilities

Sequence: 200369894
Name Karolinska University Hospital
City Stockholm
Zip 17176
Country Sweden

Conditions

Sequence: 52251288 Sequence: 52251289
Name Glioblastoma Name Surgical Margin
Downcase Name glioblastoma Downcase Name surgical margin

Id Information

Sequence: 40217092
Id Source org_study_id
Id Value 2019-00100

Countries

Sequence: 42632022
Name Sweden
Removed False

Design Groups

Sequence: 55683033
Title Glioblastoma
Description No intervention. Observation of diffuse reflectance spectroscopy patterna are made on ex-vivo tissue samples in patients undergoing surgery for glial tumors.

Interventions

Sequence: 52564234
Intervention Type Procedure
Name Diffuse Reflectance Spectroscopy
Description Measurements of DRS patterns in extirpated tumor and cerebral tissue

Design Outcomes

Sequence: 177672270
Outcome Type primary
Measure DRS pattern
Time Frame simultaneously with surgery
Description Diffuse Reflectance Spectroscopy pattern in tissue type

Browse Conditions

Sequence: 193793259 Sequence: 193793260 Sequence: 193793261 Sequence: 193793262 Sequence: 193793263 Sequence: 193793264 Sequence: 193793265 Sequence: 193793266 Sequence: 193793267 Sequence: 193793268
Mesh Term Glioblastoma Mesh Term Astrocytoma Mesh Term Glioma Mesh Term Neoplasms, Neuroepithelial Mesh Term Neuroectodermal Tumors Mesh Term Neoplasms, Germ Cell and Embryonal Mesh Term Neoplasms by Histologic Type Mesh Term Neoplasms Mesh Term Neoplasms, Glandular and Epithelial Mesh Term Neoplasms, Nerve Tissue
Downcase Mesh Term glioblastoma Downcase Mesh Term astrocytoma Downcase Mesh Term glioma Downcase Mesh Term neoplasms, neuroepithelial Downcase Mesh Term neuroectodermal tumors Downcase Mesh Term neoplasms, germ cell and embryonal Downcase Mesh Term neoplasms by histologic type Downcase Mesh Term neoplasms Downcase Mesh Term neoplasms, glandular and epithelial Downcase Mesh Term neoplasms, nerve tissue
Mesh Type mesh-list Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor

Sponsors

Sequence: 48394541 Sequence: 48394542
Agency Class OTHER Agency Class INDUSTRY
Lead Or Collaborator lead Lead Or Collaborator collaborator
Name Karolinska University Hospital Name Philips Healthcare

Overall Officials

Sequence: 29328999
Role Principal Investigator
Name Oscar Persson, MD, PhD
Affiliation Karolinska University Hospital

Design Group Interventions

Sequence: 68257259
Design Group Id 55683033
Intervention Id 52564234

Eligibilities

Sequence: 30812130
Sampling Method Non-Probability Sample
Gender All
Minimum Age N/A
Maximum Age N/A
Healthy Volunteers No
Population All patients undergoing surgical resection of glial tumors or non-neoplastic cerebral lesions at Karolinska University Hospital
Criteria Inclusion Criteria: Patients undergoing surgical resection of glial tumor or epileptic focus Exclusion Criteria: Unable to give informed consent
Adult True
Child True
Older Adult True

Calculated Values

Sequence: 254051283
Number Of Facilities 1
Registered In Calendar Year 2021
Actual Duration 44
Were Results Reported False
Has Us Facility False
Has Single Facility True
Number Of Primary Outcomes To Measure 1

Designs

Sequence: 30558105
Observational Model Cohort
Time Perspective Cross-Sectional

Responsible Parties

Sequence: 28924494
Responsible Party Type Principal Investigator
Name Oscar Persson
Title MD, PhD
Affiliation Karolinska University Hospital